Scholar Rock Holding

Rank#2748

Market Cap6.33B

CountryUnited States

Summary

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

History

Scholar Rock was founded in 2014 by PureTech Health, an advanced biotherapeutics company. Scholar Rock was established as an independent biopharmaceutical company focused on developing therapeutics targeting pathways that regulate the balance between cell and muscle growth and remodeling.

Mission

To discover and develop medicines that significantly improve the lives of people with diseases of muscle, cell, and nerve growth and differentiation.

Vision

Scholar Rock seeks to become a leader in the development of innovative medicines for muscle and cell growth and differentiation.

References

https://in.investing.com/equities/scholar-rock-holding-corp

https://www.comparably.com/companies/comparably

https://www.crunchbase.com/organization/scholar-rock

https://finance.yahoo.com/q?s=srrk

https://scholarrock.com

https://sec.report/CIK/0001727196

Leadership team